Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
NCT 05199753 Brief Summary This is a first-in-human, Phase I/II, open-label, multi-centre,…
Read more arrow_forwardNCT 05199753 Brief Summary This is a first-in-human, Phase I/II, open-label, multi-centre,…
Read more arrow_forwardNCT 02628067 Brief Summary In this study, participants with multiple types of…
Read more arrow_forwardNCT 03821935 Brief Summary The study will determine the recommended Phase 2…
Read more arrow_forwardNCT 04665206 Brief Summary This is an open-label, dose escalation and expansion…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this…
Read more arrow_forwardNCT 06003621 Brief Summary This phase II study will explore the effect…
Read more arrow_forwardNCT 05356741 Brief Summary This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation…
Read more arrow_forwardNCT 04589845 Brief Summary TAPISTRY is a Phase II, global, multicenter, open-label,…
Read more arrow_forward